Urodynamic and Clinical Efficacy of Mirabegron
AMONG NEUROGENIC BLADDER PATIENTS

PROJECT CO-FUNDER
Astellas Pharma Canada, Inc. is committed to providing patients, customers, community and employees with a bright future by changing tomorrow. This commitment is made possible because it is a different kind of pharmaceutical company. Headquartered in Markham, Ontario, Astellas Pharma Canada, Inc. is recognized as the first Japanese pharmaceutical company in Canada.

PROJECT PURPOSE
The purpose of this multi-centre, randomized, placebo-controlled study is to assess the use of mirabegron for the treatment of neurogenic bladder dysfunction.

TECHNOLOGY OVERVIEW
People with spinal cord injury (SCI) often suffer from neurogenic bladder dysfunction, causing symptoms of urinary urgency, increased urinary frequency and urinary incontinence, which can significantly reduce their quality of life. This is commonly treated with anticholinergic medication, which is associated with undesirable side effects including dry mouth, cognitive changes and constipation. Mirabegron is a new medication for overactive bladder that causes bladder relaxation, which may be able to reduce negative bladder symptoms for SCI patients with minimal side effects.
This project (G2015-12 and G2015-13) is supported through a contribution from Western Economic Diversification Canada. The views expressed herein represent the views of the Rick Hansen Institute.

The Rick Hansen Institute is a Canadian-based not-for-profit organization with the goal of creating a world without paralysis after spinal cord injury. It works towards this goal by accelerating research and translating clinical findings into practical solutions to develop new treatments, improve health care outcomes, reduce long-term costs and improve the quality of life for those living with spinal cord injury. www.rickhanseninstitute.org

TIMELINE

- Enrollment currently underway
- Recruiting 144 subjects
- 10 weeks study duration for each subject (intervention & follow-up)

NEXT STEPS

The need for a larger clinical trial will be assessed based on the data from this study.

PROJECT TEAM

**Principal Investigator**
Dr. Blayne Welk, Western University
Dr. Karen Ethans, University of Manitoba

**Investigative Team**
Dr. Alan Casey, University of Manitoba
Dr. Robert Bard, University of Manitoba
Dr. Michael Namaka, University of Manitoba
Jessie Shea, University of Manitoba
Mary McKibbon, St. Joseph’s Hospital

**Contact**
Jonathan Miodowski
Manager, Commercialization & Industry Relations
604-827-1676
jmiodowski@rickhanseninstitute.org

**Learn More**
rickhanseninstitute.org
astellas.ca